We will focus primarily on biofluid-based molecular biomarkers
On 20 & 21 February 2020, Lisbon (Portugal) will host the BioTech Pharma Summit: Liquid Biopsy 2020 conference. This year’s event will bring together the leaders in the field from pharma, biotech, Dx companies and healthcare and be the home of multi-stakeholder and pan-industry collaboration for liquid biopsy, molecular pathology and precision medicine experts to explore the expanding and evolving field whereby Circulating Biomarkers of various classes are being evaluated for their potential to be developed into diagnostics for cancer as well as application of liquid biopsy testing, across biofluids, biomarkers and disease indications, as the needle shifts on the gold standard of personalized healthcare testing.
The field of liquid biopsy is moving beyond isolation and characterization of CTCs and ctDNA to surveillance, early detection of relapse and minimal residual disease, and interventional studies in clinical applications. The scope of the conference encompasses circulating tumor cells, cell-free circulating DNA, exosomes and extracellular vesicles. This meeting has become an important annual event for leaders in the community to discuss the tools, validation and implementation of circulating biomarkers, which are transforming our understanding and management of disease.
The Liquid Biopsy 2020 focuses primarily on biofluid-based molecular biomarkers, such as circulating tumor DNA (ctDNA) as well as circulating tumor cells (CTCs), and protein-based circulating biomarkers. There is much interest in the potential of ctDNA for developing biological fluid-based biopsies (such as using plasma, urine, or other biofluids) and the presenters in this track bring together the most up-to-date information and current state-of-the-field.